Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ5104
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral (research Use)
01
Overview
AZ5104 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and a demethylated metabolite of osimertinib. It acts as an EGFR tyrosine kinase inhibitor and is also identified as a specific agonist for the nuclear receptor RORγ, showing agonist effects in certain cell models (HepG2), while exerting inhibitory effects on RORγT expression and Th17-related cytokine production in immune cells. Its biological effects are due both to direct receptor interactions and inhibition of downstream EGFR signaling pathways, impacting immune and metabolic pathways. AZ5104 has been explored primarily in research settings for its implications in oncology and immune modulation[1].
- Other names
- AZ5104AZ-5104AZ 5104
02
Targets
RORC (Retinoic acid receptor-related orphan receptor gamma)STAT3 (Signal Transducer and Activator of Transcription 3)EGFR T790M (Epidermal growth factor receptor T790M mutant)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on AZ5104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ5104.